The company has established CRO partnerships with several domestic and international companies, such as Heze Pharma, Zhiheng Pharmacy, and Chempion Pharm-Tech. Additionally, the company has entered into CMO collaborations with well-known domestic pharmaceutical companies such as Neptunus Group, Xinhua Pharma, Humanwell Pharma. etc.
The company has invested over 50 million yuan in R&D funds. The MAH products cover various dosage forms, including oral solution, powder for suspension, lyophilized powder for injection, inhalation preparations, and large volume infusions. In the future, the company plans to collaborate with innovative research institutions to focus on high-end formulations, such as nanoemulsions, nanocrystals, and 3D printing, in order to add new impetus to the company's development.